Immunovaccine Signs Licensing Deal with Pfizer Animal Health to Develop a Third Livestock Vaccine
Immunovaccine Inc. has announced that Pfizer Animal Health, a business of Pfizer Inc., will exercise a licensing option on the company's vaccine enhancement and delivery platform to develop a third livestock vaccine. This represents an important milestone for Immunovaccine as it further validates the potential of its vaccine platform, and enables the Company to apply the upfront signing fees, and any milestone and royalty payments to further advance its vaccine pipeline.
"We are pleased that Pfizer Animal Health will now be integrating our technology into a third vaccine product," said Dr. Randal Chase, president and CEO of Immunovaccine.
Immunovaccine's patented vaccine enhancement platform uses liposomes in an oil depot to present antigens and adjuvants to the immune system. In preclinical models, the platform creates a depot effect that prolongs the immune system's exposure to the vaccine, resulting in a rapid, potent, and long lasting immune response after a single dose.
Vaccinations are among the most effective tools to ensure healthy livestock for a safe, global food supply.